- Raised $7M Series B led by UroGen Pharma Ltd., Aug 2026
- Raised $1M Series A led by Arieli Group, Jul 2022
- Raised $1M Seed round led by Arieli Group, Nov 2020
About
IntraGel Therapeutics is a research-driven company focused on pioneering advanced treatments for solid tumors using its SRGel platform, a gel-based drug delivery technology. This injectable polymeric platform solidifies once injected into the body, slowly releasing trapped drugs over weeks to the surrounding area. The SRGel platform is designed to deliver sustained efficacy with minimal frequency and can be combined with various anti-cancer medications, such as cisplatin (its flagship product, TumoCure), paclitaxel, and temozolamide. The company is targeting head and neck cancer as its initial indication, aiming to provide a treatment option for patients unfit for conventional chemotherapy. IntraGel Therapeutics operates from the NGT3 technology incubator in Nazareth, Israel. The company is currently raising $5 million to advance FDA IND enabling studies, establish a GMP facility, and progress towards Phase II clinical trials.
Funding history · 3 rounds · $9.0M total
Headcount over time
Offices
Q&A
- What is IntraGel Therapeutics' primary focus?
- IntraGel Therapeutics is a research-driven company focused on pioneering advanced treatments for solid tumors using its SRGel platform, a gel-based drug delivery technology.
- When was IntraGel Therapeutics founded?
- IntraGel Therapeutics was founded in December 2020.
- What is the total amount of funding IntraGel Therapeutics has raised to date?
- IntraGel Therapeutics has raised a total of $8,000,000 USD.
- What is IntraGel Therapeutics' current employee count?
- IntraGel Therapeutics has 5 employees, falling within the 1-10 employee bucket.
- Where is IntraGel Therapeutics headquartered?
- IntraGel Therapeutics is headquartered in Nazareth, Israel.
- Which investors participated in IntraGel Therapeutics' Seed round in July 2022?
- The Seed round in July 2022 was led by MassChallenge and NGT HealthCare II
- What is the purpose of IntraGel Therapeutics' SRGel platform?
- The SRGel platform is an injectable polymeric platform designed to solidify once injected into the body, slowly releasing trapped drugs over weeks to the surrounding area for sustained efficacy.
- What is IntraGel Therapeutics' flagship product?
- IntraGel Therapeutics' flagship product is TumoCure, which combines the SRGel platform with cisplatin for cancer treatment.
- What is the initial indication IntraGel Therapeutics is targeting with its treatments?
- IntraGel Therapeutics is targeting head and neck cancer as its initial indication.
- Which investor participated in IntraGel Therapeutics' B Round in August 2026?
- UroGen Pharma invested $7,000,000 in IntraGel Therapeutics' B Round in August 2026.
Team · 4
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | intra-gel.com |
|---|---|
| linkedin.com/company/72377575 |
Identifiers & details
| Legal name | INTRAGEL THERAPEUTICS LTD |
|---|---|
| Founded | 2020-12 |
| Employees (exact) | 5 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | intra-gel.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516293677 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-12-09 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 1 — charge (1) |
| Registered address | ואדי אל-חאג' 13 נצרת |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-15 | רישום שעבוד |